北京泽辉辰星生物科技

Zehui Chenxing is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of pluripotent stem cell (PSC)-derived regenerative medicines. The company leverages its proprietary platform to differentiate embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into functional therapeutic cells for high-unmet-need diseases. Its lead candidate, ZH901, is a human ESC-derived mesenchymal stem cell therapy currently in Phase 2 clinical trials for Acute Respiratory Distress Syndrome (ARDS). Beyond respiratory health, the company is advancing a diverse pipeline targeting neurodegenerative disorders, such as Parkinson's disease, and orthopedic conditions like meniscus injuries. Zehui Chenxing has secured significant backing from prominent investors including Legend Capital and Qiming Venture Partners to support its manufacturing and clinical expansion.